FGF-23 has emerged as an early biomarker of cardiovascular change [20], and circulating FGF-23 connects to the primary adverse clinical outcomes in CKD, such as ESRD, cardiovascular events, and mortality [21]. This evidence concerns the gene FGF23 and chronic kidney disease.